http://pharmasprings.com/ijcpms/issue/feed International Journal of Clinical Pharmacokinetics and Medical Sciences 2024-02-02T15:59:48+0530 Editor editorijcpms@pharmasprings.com Open Journal Systems <div> <img style="width: 100%;" src="https://pharmasprings.com/templates/frontend/pages/slideshow/slideshow2.gif" /></div> <p align="justify">International Journal of Clinical Pharmacokinetics and Medical Sciences <em>(IJCPMS)</em> ISSN: 2583-0953 is established in the year 2021 officially sponsored by <em><strong>pharma springs publication</strong></em>. We are pleased to introduce ourselves as the novel imminent, and sovereign online pharmacy &amp; medical information services in India. The foundation aims to serve as a means for updating the scientific knowledge of the international audience in the research field of science so a correlation can be made between these researchers. IJCPMS will be published quarterly per year in March, Jun, September, and December. The journal publishes the work that contributes significantly to further the scientific knowledge in the areas of pharmaceutical, medical &amp; biological sciences. All contributions to the journal are rigorously refereed and are selected based on the quality and originality of the work.</p> http://pharmasprings.com/ijcpms/article/view/573 Formulation and Evaluation of Phenylephrine Nasal Gels 2024-02-01T23:24:44+0530 Ameer Pasha Shaik adapa.sowmy@gmail.com Sowmy Adapa adapa.sowmy@gmail.com <p>The primary objective of this study is to develop and evaluate phenylephrine nasal gels, aiming for stable blood levels with lower drug doses through consistent administration, avoiding first-pass hepatic metabolism. Compatibility among the drug, polymers, and lipids was confirmed using FTIR and DSC spectra. Phenylephrine nasal gels were formulated, and their clarity assessed. The gels (ONGF1-ONGF8) had pH values of 6.1-7.2, spreadability of 18.33-21.62 g/cm/sec, and viscosity of 934.2-966.2 centipoises. Drug concentration in these formulations varied from 85.52% to 98.88%, indicating acceptable medication content. Gel strength ranged from 64% to 95%. In-vitro drug release of phenylephrine showed 77% to 95% diffusion for ONGF1. The release kinetics followed first order, zero order, Higuchi model, and Korsemeyer-Peppas equations. Kinetic values for all formulations were tabulated. ONGF1 exhibited the most efficient release, with 95% of the drug released within 7 hours, demonstrating a diffusion mechanism followed by non-Fickian transport, adhering to both zero order and Korsemeyer-Peppas models.Top of Form</p> 2024-02-02T00:00:00+0530 Copyright (c) 2024 International Journal of Clinical Pharmacokinetics and Medical Sciences http://pharmasprings.com/ijcpms/article/view/574 A prospective study on assessment of risk factors, clinical characteristics and outcomes of acute pancreatitis in a tertiary care center 2024-02-02T15:50:13+0530 Radhika Chikatipalli drradhika@svcop.in Asifa Banu Mohammad drradhika@svcop.in Audi Narayana Nelavala drradhika@svcop.in <p>This prospective study at RVS Hospital Chittoor targets acute pancreatitis, a severe pancreatic condition with significant health risks. Its goal is to improve patient care by analyzing risk factors, clinical features, and outcomes. Adult patients with acute pancreatitis will participate, providing comprehensive demographic, clinical, and lab data. The research will focus on key risk factors like alcohol use, gallstones, and prior pancreatitis episodes. Clinical aspects, including pain severity, systemic symptoms, and complications, will be documented, utilizing CT scans and MRI for accurate diagnosis and classification. The primary aims are identifying acute pancreatitis risk factors, understanding patient presentations, and monitoring complications during hospitalization. Secondary goals include evaluating the impact of risk factors on disease severity and mortality and exploring connections between specific risks and major complications like pancreatic necrosis and infections. This study is crucial for advancing understanding of acute pancreatitis, guiding healthcare professionals in early diagnosis, risk stratification, and effective management, ultimately enhancing patient outcomes in this complex medical issue.</p> 2024-02-02T00:00:00+0530 Copyright (c) 2024 International Journal of Clinical Pharmacokinetics and Medical Sciences http://pharmasprings.com/ijcpms/article/view/575 A Prospective Study of Disease Patterns and Assessment of Drug Interactions with Prasugrel in Tertiary Care Hospital Patients 2024-02-02T15:59:48+0530 Kishore Bandarapalle kishore.brr89@gmail.com Hemanth Yadav Mopuru kishore.brr89@gmail.com Mohammad Ishaqulla Kodadhavadi kishore.brr89@gmail.com Saran B kishore.brr89@gmail.com Sree Harsha Avvaru kishore.brr89@gmail.com Likhith C kishore.brr89@gmail.com Mujeeb Shaik kishore.brr89@gmail.com <p>This prospective observational study evaluates the prescribing patterns and drug-drug interactions of Prasugrel in hospitalized patients at a tertiary care hospital (BBH). Conducted over six months, it involved 110 inpatients, gathering data from various sources including patient profiles, medicine charts, and lab tests. The study primarily focused on Prasugrel usage, identifying patient demographics and assessing the interactions of Prasugrel with other medications. It found that 64.02% of the patients on Prasugrel therapy were male and 36.08% female, predominantly aged between 55 to 75 years. These patients often had a history of cardiovascular and infectious diseases. The study revealed that 31.36% of patients experienced interactions with Prasugrel, with a higher incidence in males. The most common interactions were with Pantoprazole, Omeprazole, and Aspirin. These interactions were classified as severe (11.81%), moderate (55.05%), and mild (34.13%). Additionally, 17.91% of interactions were defined, 58.45% probable, and 22.62% possible. Prasugrel was mainly prescribed for heart disease, myocardial infarction, and angina. The study suggests cautious use of Pantoprazole with Prasugrel due to potential significant interactions.</p> 2024-02-02T00:00:00+0530 Copyright (c) 2024 International Journal of Clinical Pharmacokinetics and Medical Sciences